  |
 |
 Key drug R&D management
Samantha Du, Ph.D., Chief Scientific Officer, Chi-Med
| |||||
Samantha Du, Ph.D. Dr. Du is the CEO of Hutchison Medipharma Limited (HMPL) and Chief Scientific Officer of Chi-Med. Dr. Du joined Hutchison Whampoa China Limited (HWCL) in 2001 as Executive VP -- Healthcare Investments and was one of the founders of Chi-Med. She played a key role in the successful IPO of Hutchison Chi-Med in London in May 2006. With the financial backing of HWCL, Dr. Du founded Hutchison Medipharma in 2002. Dr. Du received her Ph.D. in Biochemistry from University of Cincinnati. Prior to Hutchison, she was in Pfizer’s global strategic operation division responsible for global licensing and related M&A activities for metabolic diseases. She started her research career at Pfizer Connecticut and led teams that involved in multiple early and late stage product development in different therapeutic areas and two successful product launches. She is currently an active advisor on healthcare and biotech issues for various government agencies and research institutions in China. |
|||||
|
|||||
Weiguo Su, Ph.D. Dr. Su joined Hutchison MediPharma in 2005, prior to which he spent fifteen years in Pfizer's US R&D organisation. Dr. Su delivered several high quality new drug candidates during his time with Pfizer with his last role being a director in the Medicinal Chemistry Department. He received his Ph.D. and post-doctoral fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China. |
|
||||
|
|||||
Jimmy Wei, Ph.D., MBA Dr. Wei has over ten years of experience in the life sciences industry, in the areas of R&D, investment and business development. Dr. Wei is Vice President and head of the business development at Hutchison MediPharma. Previously, Dr. Wei was the Deputy General Manager of Burrill China Group, where he led Burrill’s business activities related to Greater China Area. Burrill is one of the largest life sciences VC fund with close to $1bln under management. Prior to joining Burrill, Dr. Wei worked for WI Harper Group (WIH) and oversaw its global life sciences investment. Before WIH, Dr. Wei was a management consultant at McKinsey Shanghai office. Dr. Wei has also conducted R&D in several leading research organizations, including Duke University Medical Center and Chinese Academia of Sciences. Dr. Wei has obtained a Ph.D. in Biochemistry from North Carolina State University. He also holds an M.B.A. from Darden Business School, University of Virginia. |
|
||||
|
|||||
Xun Zhang, Ph.D. Dr. Zhang joined Hutchison MediPharma in 2005, prior to which he spent eleven years in Pfizer's US R&D organisation where he was a director in the Pharmaceutical Sciences Division and, before that, four years at the Bristol-Myers-Squibb Research Institute. Dr. Zhang received his Ph.D. in Chemistry from the University of Texas at Austin and his Bachelor's degree in Chemistry from Peking University, China. |
|
||||
|
|||||
Zhenping Wu, Ph.D. MBA Dr. Wu joined Hutchison MediPharma in 2008 with 17 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. His past positions include Senior Director of Pharmaceutical Sciences at Phenomix Corporation, a California based drug discovery and development company, Director of Pharmaceutical Development at Pfizer Global Research & Development in San Diego, California (formerly Agouron Pharmaceuticals), and Senior Scientist at Roche Palo Alto site. Dr. Wu led many development project teams and advanced numerous drug candidates into different phases of clinical development and commercialization. The candidates include Sutent, a new blockbuster anti-cancer drug for Pfizer. Dr. Wu received a Ph. D. degree from Hong Kong University, and an MBA degree from the University of California at Irvine. He is a past Chairman and President of the Board of Sino-American Biotechnology and Pharmaceutical Association. He received a Colleague Recognition Award from Pfizer in 2003 for his work on the Sutent project, a Dean's Scholar Award from the University of California at Irvine in the same year, and a Leadership Award from the Sino-American Biotechnology and Pharmaceutical Association in 2008. Dr. Wu was the recipient of an American Heart Association Fellowship in 1990. |
|
||||
|
|||||
Tom Tang, M.D., MBA Dr. Tang joined Hutchison MediPharma in 2007, prior to which he was a clinical program leader in Pliva Inc. and Pfizer/Pharmacia. Dr. Tang has more than 15 years experience in infectious diseases, immunology, endocrinology, and oncology. He received his Medical Degree from Capital University of Medicine in Beijing, China and his Master's degree in Business Administration from Rutgers University, the State University of New Jersey. |
|
||||
|
|||||
Mark Lee, MBA Mr. Lee joined Hutchison MediPharma in 2009, prior to which he had been working in healthcare investment banking in the United States and Europe since 1998. Mr. Lee was a Vice President at Credit Suisse, a multinational financial services company with an extensive global healthcare practice. Based in the New York and London offices of Credit Suisse, Mr. Lee was involved in the execution and origination of mergers, acquisitions, public and private financings, and corporate strategy for life science companies such as AstraZeneca, Bristol-Myers Squibb, Genzyme and Nanosphere, amongst others. Mr. Lee also spent time with the Business Development department of Bristol-Myers Squibb, focused on in-licensing. Mr. Lee received his Bachelor of Engineering in Biochemical Engineering with First Class Honours from University College London, where he was awarded a Dean's Commendation. He also received a Master of Business Administration from the Massachusetts Institute of Technology, Sloan School of Management. |
|
||||
|
|||||
| Copyright 2010 Hutchison China MediTech Limited. All rights reserved. Disclaimer |